About CB Therapeutics
CB Therapeutics is a startup developing a novel process for the production of non-psychoactive cannabinoid compounds that are currently in high demand in the medical cannabis (medical marijuana) market. These particular cannabinoids do not produce a “high” or have potential for abuse and are already sold in the market similar to supplements.
A Novel Idea Brought to Life at the Rady School
Before coming to Rady, CB Therapeutics was just an idea I had been researching for a couple years while working as the Lab Director at Steep Hill Halent, the largest medical cannabis testing laboratory in the US. While at Steep Hill, I came across many patients, doctors, and other industry associates who were quite passionate about non-psychoactive cannabinoids as opposed to THC. Since the largest portion of cannabinoids in the cannabis plant is THC, these other molecules are very rare and expensive to extract. Instead of growing plants like the current practice, I realized that by applying biotechnology to this industry I could bring down the cost of production while creating specific molecules, each with their own properties, that are currently not available in the market today. I started my own research and eventually decided to quit my job, enroll in business school, and try to manifest my idea into a business.
Opportunities available for entrepreneurs such as the StartR accelerator and Lab to Market capstone course series are the main reasons I decided to pursue my MBA at the Rady School. StartR in particular gave me a lot of confidence in CB Therapeutics and introduced me to the best mentors for my specific business, along with access to all the information I needed to create my startup. I am very satisfied with the experience, and would encourage anyone passionate about their idea and ready to move it to the next level to apply. I am also grateful for the UC San Diego Entrepreneur Challenge (where CB Therapeutics recently placed third in the Bio/Med finals) and other entrepreneur events all over San Diego that enabled me to hone my entrepreneurial skills and compete for funding.
Today, the CB Therapeutics team has expanded greatly and is comprised of myself (with five years of experience as a biochemist working in the biotech/pharma and medical cannabis industries), our Chief Medical Officer (a doctor in the Bay Area), and our Chief Regulatory Officer (who setup many cannabis businesses across the US and is currently helping certain state governments draft legislature for the testing, quality assurance, and regulation of medical cannabis). We also have two dedicated Rady School students on our team helping part-time and three amazing mentors with extensive business, biotech, nutraceutical and startup experience.
On the Horizon
CB Therapeutics aims to complete our research and bring the product to market by next year. We have filed our patent for the biosynthesis of our compounds and have plans to create an IP portfolio down the road. We are also talking to a few different cancer and epilepsy organizations that are involved with giving patients free non-psychoactive cannabinoids or conducting studies/trials with the cannabinoid Cannabidiol (CBD). Our business model calls for CB Therapeutics to give away five percent of our profits in cannabinoids each year to an organization of our choice. We will give these profits in cannabinoids instead of cash as our manufacturing process can produce these compounds for 1/4th the cost of traditional plant-extracted cannabinoids. Additionally, we want to create value for the patients versus just giving out a check.
In the coming months, we plan to raise funds via crowdfunding. Check out our website (www.cbth.org) and Facebook/Twitter pages for more details.
More on the Rady School’s StartR Accelerator
StartR is a six-month, nonprofit accelerator designed to help Rady School of Management students and alumni to create profitable companies based on their innovative ideas. The program focuses on hands-on company development and teams are mentored by experienced entrepreneurs. In the last three years, 80% of StartR’s teams have been incorporated.
Want to learn more about the Rady School of Management’s innovative and entrepreneurship-focused MBA program? Download our MBA insights eBook, featuring where alumni work, support available for student entrepreneurs at Rady and more.
Sher Ali Butt is a full-time Rady School MBA candidate (’16) and the Founder of CB Therapeutics. He has five years of experience as a biochemist working in the biotech/pharma and medical cannabis industries.